AMERICAN HEALTH CARE
DRUG PRODUCTS & SAFETY NEWS

Discontinuation of Valsartan and Hydrochlorotiazide Tablets

February 16, 2016

Sandoz Inc. reported to the U.S. Food and Drug Administration (FDA) the discontinuation of valsartan and hydrochlorotiazide tablets.

Presentation	Related Information
80/12.5 mg Bottle of 90 (NDC 0781-5948-92)	Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.
160/12.5 mg Bottle of 90 (NDC 0781-5949-92)	
160/25 mg Bottle of 90 (NDC 0781-5950-92)	
320/12.5 mg Bottle of 90 (NDC 0781-5951-92)	
320/25 mg Bottle of 90 (NDC 0781-5952-92)	

Sandoz Inc, Company Contact Information: 800-525-8747

Source:
http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Valsartan+and+Hydrochlorothiazide+Tablet%2C+Film+Coated&source=govdelivery&st=d&tab=tabs-4&utm_medium=email&utm_source=govdelivery